- News Home
12 December 2013 1:00 pm ,
Vol. 342 ,
The iconic 125-year-old Lick Observatory on Mount Hamilton near San Jose, California, is facing the threat of closure...
Recent results from the Curiosity Mars rover have helped scientists formulate a plan for the next phase of its mission...
A new, remarkably powerful drug that cripples the hepatitis C virus (HCV) came to market last week, but it sells for $...
In pretoothbrush populations, gumlines would often be marred by a thick, visible crust of calcium phosphate, food...
Evolutionary biologists have long studied how the Mexican tetra, a drab fish that lives in rivers and creeks but has...
Victorian astronomers spent countless hours laboriously charting the positions of stars in the sky. Such sky mapping,...
In an ambitious project to study 1000 years of sickness and health, researchers are excavating the graveyard of the now...
Stefan Behnisch has won awards for designing science labs and other buildings that are smart, sustainable, and...
- 12 December 2013 1:00 pm , Vol. 342 , #6164
- About Us
A Deadly Peek at Fungal Medusa
22 January 1997 8:00 pm
If looks can kill, why not try look-alikes? Scientists have used a molecular imprint--something akin to a plaster cast--of a fungus-killing compound produced by yeast to make a protein that appears to be lethal to a common fungus that infects people. The finding, reported in next month's issue of Nature Biotechnology, could lead to a therapy for vaginal fungal infections in women and oral fungal infections in AIDS patients.
A team led by Luciano Polonelli, a microbiologist at Università degli Studi de Parma, began its quest for a mirror-image killer with a type of yeast that produces a toxin against fungi that attack it. The toxin itself would be too toxic as a drug for people, so the group took a different tack. They raised antibodies to this toxin in cell culture, then injected the antibodies into a mouse. The mouse immune system, encountering the foreign protein, produced antibodies to the antibodies-tongue twisters that scientists call antiidiotypic antibodies, or anti-Ids.
The scientists isolated from mouse spleen cells 10 anti-Ids. They put the most potent to the test of combating Candida albicans, the culprit behind vaginal fungal infections. Rats infected with Candida and given injections of the anti-Id were cured much faster than were rats given a placebo.
Experts say the preliminary study is promising. "This is the first time I'm aware of where an antibody behaves like an antibiotic," says Neil Greenspan, an immunologist at Case Western Reserve University in Cleveland. The next step would be to do tests in other animal models. Adds Barry Fields, a biochemist at the Center for Advanced Research in Biotechnology at the University of Maryland, "This is certainly promising in terms of therapeutics."